Agreement - March 7, 2022
Vakona signs agreement with GTP Tech
Vakona has signed an agreement with French company GTP Tech to initiate the first manufacturing steps of its acne medicine. GTP Tech, a GTP Bioways company, will develop the industrial process to move on from the preclinical phase towards the manufacturing of antibiotic-free treatment for clinics. “This agreement is a big step forward for us. […]
Agreement - March 1, 2022
AstraZeneca and Neurimmune close collaboration and licence agreement
Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006. NI006 is an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), an underdiagnosed, systemic condition that leads to progressive heart failure and high rate of fatality within […]
Agreement - February 23, 2022
Zerion Pharma and Hovione enter strategic partnership
Zerion Pharma has entered into a strategic partnership with Hovione to accelerate the commercialization of the Dispersome technology. Through their partnership, the two companies are offering pharma and biotech companies worldwide access to an innovative drug delivery platform combined with an unparalleled experience in formulation development, scale up and GMP manufacturing, they state. This combination […]
Agreement - February 23, 2022
AstraZeneca enters partnership with Honeywell
The two companies will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze. HFO-1234ze has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines, states AstraZeneca. “We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and […]
Agreement - February 11, 2022
Bactiguard expands partnership with Biomet
Bactiguard and Zimmer Biomet have agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), sports medicine, craniomaxillofacial and thoracic applications. License and development fees of 1.5 million USD payable in 2022 It includes license […]
Agreement - February 8, 2022
Xbrane Biopharma enters agreement with Biogen
The two companies have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA. CIMZIA’s primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn’s disease. In 2020 global sales of CIMZIA were 1.8 billion […]
